Background/Aims: The influence of type of surgery and occurrence of post-operative complications on survival following adjuvant therapy for pancreatic cancer are uncertain. Methods: Cox proportional hazard modelling was used to investigate the influence of type of surgery and the presence of complications on survival in conjunction with clinico-pathological variables in the 550 patients of the ESPAC-1 adjuvant randomized controlled trial. Results: Standard Kausch-Whipple (KW) was performed in 282 (54%) patients, 186 (35%) had a pylorus-preserving (PP) KW, 39 (7%) had a distal pancreatectomy and 21 (4%) had a total pancreatectomy. Post-operative complications were reported in 140 (27%) patients. PP-KW patients survived longer with a median (95% CI) survival of 19.9 (17.3, 23.1) months compared to 14.8 (13.0, 16.7) for KW patients (χ2LR = 15.1, p < 0.001). KW patients were more likely however to have R1 margins (67 (24%) vs. 29 (16%), χ2 = 4.59, p = 0.032), poorly differentiated tumours (70 (26%) vs. 19 (10%), χ2 = 18.65, p < 0.001) and positive lymph nodes (165 (60%) vs. 81 (44%), χ2 = 11.32, p < 0.001). Post-operative complications did not significantly affect survival. Independent prognostic factors were tumour grade, nodal status and tumour size but not type of surgery or post-operative complications. There was a survival benefit for chemotherapy irrespective of the type of surgery or post-operative complications. Conclusions: The KW and PP-KW procedures did not significantly influence the hazard of death in the presence of tumour staging, demonstrating that ESPAC-1 surgeons showed good judgement in their choice of operation. Post-operative complications did not adversely affect the survival benefit from adjuvant chemotherapy.

Keywords:
Surgery, Resection, Post-operative complications, Pancreas, Pancreatic, Cancer, Chemotherapy, Chemoradiotherapy, Randomized controlled trial
1.
Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4–S66.
2.
Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP: Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995;82:111–115.
3.
Jemal A, Murray T, Samnels A, Ghafoor A, Ward E, Thun M: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5–26.
4.
Neoptolemos JP, Russell RCG, Bramhall SR, Theis B: Low mortality following resection for pancreatic and periampullary tumours in 1,026 patients: UK survey of specialist pancreatic units. Br J Surg 1997;84:1370–1376.
5.
Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE: Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–1137.
6.
Sener S, Fremgen A, Menck H, Winchester D: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985 to 1995, using the National Cancer database. J Am Coll Surg 1999;189:1–7.
7.
Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP: Current standards of surgery for pancreatic cancer. Br J Surg 2004;91:1410–1427.
8.
Geer RJ, Brennan MF: Prognostic indicators of survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68–72.
9.
Nitecki SS, Sarr MG, Colby TV, et al: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59–66.
10.
Yeo C, Abrams R, Grochow L, Sohn T, Ord S, Hruban R, et al: Pancreaticoduodenectomy for pancreatic adenocarcinoma. Postoperative adjuvant chemoradiation improves survival: a prospective, single institution experience. Ann Surg 1997;225:621–633.
11.
Bassil C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P: Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 2001;18:453–458.
12.
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–594.
13.
Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
14.
Douglass HO: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.
15.
Bakkevold KE, Arnesjo B, Dahl O, Kambestad B: Adjuvant combination chemotherapy following radical resection of carcinoma of the pancreas and papilla of Vater – results of a controlled, prospective, randomised multicenter study. Eur J Cancer 1993;5:698–703.
16.
Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–784.
17.
Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicentre prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.
18.
Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait D, et al: Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003;14:675–692.
19.
Shore S, Raraty M, Ghaneh P, Neoptolemos JP: Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003;18:1049–1069.
20.
Abrams RA, Grochow LB, Chakravarthy A, et al: Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA 19-9 levels. Int J Radiat Oncol Biol Phys 1999;44:1039–1046.
21.
Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al: Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000;48:1483–1487.
22.
Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476–480.
23.
Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314–327.
24.
Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576–1585.
25.
Neoptolemos JP, Stocken DD, Dunn JA, et al: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758–768.
26.
Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004:350:1200–1210.
27.
Breslin TM, Hess KR, Harbison DB, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123–132.
28.
Satake K, Nishiwaki H, Yokomatsu H, et al: Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 1992;175:259–265.
29.
Takahashi S, Ogata Y, Miyazaki H, et al: Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. World J Surg 1995;19:653–659.
30.
Nagakawa T, Nagamori M, Futakami F, et al: Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640–645.
31.
Mukaiya M, Hirata K, Satoh T, et al: Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg 1998;22:248–252.
32.
Ishikawa O, Ohigashi H, Sasaki Y, et al: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1998;208:215–220.
33.
Pedrazzoli S, Di Carlo V, Dionigi R, et al: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy. In the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy study group. Ann Surg 1998;228:508–517.
34.
Yeo CJ, Cameron JL, Lillemoe KD, Sohn T, Campbell K, Sauter P, et al: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. 2. Ann Surg 2002;236:355–368.
35.
Henne-Bruns D, Vogel I, Luttges J, Klöppel G, Kremer B: Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000;24:595–601.
36.
Klinkenbijl JH, van der Schelling GP, Hop WC, van Pel R, Bruining HA, Jeekel J: The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992;216:142–145.
37.
Lin PW, Lin YJ: Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg 1999;86:603–607.
38.
Di Carlo V, Zerbi A, Balzano G, Corso V: Pylorus-preserving pancreaticoduodenectomy versus conventional Whipple operation. World J Surg 1999;23:920–925.
39.
Seiler CA, Wagner M, Sadowski C, Kulli C, Büchler MW: Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): initial clinical results. J Gastrointest Surg 2000;4:443–452.
40.
Sohn TA, Yeo CJ, Cameron JL, et al: Resected adenocarcinoma of the pancreas – 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.
41.
Roder JD, Stein HJ, Huttl W, Siewert JR: Pylorus-preserving versus standard pancreaticoduodenectomy: an analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152–155.
42.
Friess H, Yamanaka Y, Büchler M, et al: Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846–1856.
43.
Friess H, Lu Z, Andrén-Sandberg Å, Berberat P, Zimmerman A, Adler G, et al: Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228:780–787.
44.
Kawesha A, Ghaneh P, Evans JD, et al: K-ras oncogene subtype mutations are associated with survival but not the expression of p53, p16INK4a, p21WAF-1, cyclin D1, erb-B2 and erb-B3 in resected pancreatic adenocarcinoma. Int J Cancer 2000;89:469–474.
45.
Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832–2845.
46.
Kobari M, Sunamura M, Ohashi O, Saitoh Y, Yusa T, Matsuno S: Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. J Am Coll Surg 1996;182:24–32.
47.
Jones L, Russell C, Mosca F, et al: Standard Kausch-Whipple pancreatoduodenectomy. Digest Surg 1999;16:297–304.
48.
Pedrazzoli S, Beger H, Obertop H, et al: A Surgical and pathological based classification of resection of pancreatic cancer: summary of an international workshop on surgical procedures in pancreatic cancer. Digest Surg 1999;16:337–345.
49.
Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
50.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
51.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and example. Br J Cancer 1977;35:1–39.
52.
Cox DR: Regression models and life-tables. J Roy Stat Soc (B) 1972;34:187–220.
53.
Early Breast Cancer Trialists’ Collaborative Group: Introduction and methods sections reproduced from ‘Treatment of Early Breast Cancer, vol 1. Worldwide Evidence 1985–1990’. Oxford, Oxford University Press, 1990.
54.
Qian W, Parmar MKB, Sambrook RJ, Fayers P, Girling D, Stephens R: Analysis of messy longitudinal data from a randomised clinical trial. Stat Med 2000;19:2657–2674.
55.
Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I: Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 1994;73:1155–1162.
56.
Nakao A, Harada A, Nonami T, et al: Lymph node metastases in carcinoma of the head of the pancreas region. Br J Surg 1995;82:399–402.
57.
Ishikawa O, Ohigashi H, Sasaki Y, et al: Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997;121:244–249.
58.
Kayahara M, Nagakawa T, Ohta T, et al: Analysis of paraaortic lymph node involvement in pancreatic carcinoma: a significant indication for surgery? Cancer 1999;85:583–590.
59.
Connor S, Bosonnet L, Ghaneh P, Alexakis N, Hartley M, Campbell F, Sutton R, Neoptolemos JP: Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. Br J Surg 2004;91:1592–1599.
60.
Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA: Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am 2004;13:639–661.
61.
Halloran CM, Ghaneh P, Bosonnet L, Hartley MN, Sutton R, Neoptolemos JP: Complications of pancreatic cancer resection. Dig Surg 2002;19:138–146.
62.
Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JHG, Bakkevold KE, Takada T, Amano H, Neoptolemos JP, on behalf of the Pancreatic Cancer Meta-Analysis Group: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372–1381.
63.
Tran KT, Smeenk HG, van Eijck CH, Kazemier G, Hop WC, Greve JW, Terpstra OT, Zijlstra JA, Klinkert P, Jeekel H: Pylorus- preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004;240:738–745.
64.
Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Büchler MW: Randomized clinical trial of pylorus- preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg 2005;92:547–556.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.